Accretive Health Completes Financial Restatement and Provides Business Update

Accretive Health, Inc. (OTC Pink:

) today announced that it has completed its financial restatement and filed its Annual Report on Form 10-K for the year ended December 31, 2013, which also includes results for the year ended December 31, 2012 and restated results for the year ended December 31, 2011. “Completing the restatement is an important milestone for Accretive Health, and we appreciate the patience of our customers and shareholders as we worked through this process, as well as our employees for continuing to deliver outstanding service to our customers,” said Emad Rizk, M.D., President and Chief Executive Officer of Accretive Health. “While the restatement put our financial reporting on hold, we have focused on improving our operational execution and advancing our IT infrastructure during this period.” The most significant result of the restatement is that, under generally accepted accounting principles (GAAP), the vast majority of revenue generated from Accretive Health's revenue cycle agreements is recognized in periods substantially later than when the Company provides services to its customers. Revenue recognition occurs when Accretive Health and its customers reach a final determination of the value generated under the Company's performance-based contracts. As a result, the Company believes that GAAP financial measures, on their own, may not provide shareholders with a full understanding of the Company's operating and financial performance. Accordingly, the Company is focusing on certain non-GAAP measures to evaluate and convey additional information concerning its operating and financial performance. These non-GAAP measures are gross cash and net cash generated from customer contracting activities, each of which is described below. Over the past year, Accretive Health has improved its operational discipline across the Company by strengthening its front line teams and standardizing service delivery models. These improvements, combined with an increase in technology investment in 2014, have led to greater predictability and accountability in the value delivered to the Company's healthcare provider customers. In addition, the Company has strengthened its management team and Board of Directors, adding executives with strong operational experience and deep healthcare expertise. “As reimbursement models in the healthcare industry evolve toward risk-sharing and the proactive management of patient populations, Accretive Health offers broad capabilities, delivered in collaboration with our customers, to help them address these financial and administrative challenges.” Rizk said. “Strategically this requires the deliberate and structured integration of our operational units into a comprehensive, but flexible end-to-end revenue cycle management solution, delivering predictable and measurable outcomes and operational excellence to our customers.” Rizk added “Accretive Health moves forward with a renewed growth focus that offers its integrated revenue cycle expertise and analytics to large integrated delivery networks, which are being challenged by meeting the complexities associated with multiple value-based payment models.” Peter Csapo, Chief Financial Officer and Treasurer, commented, “We are focused on managing our business with rigor and discipline. We are improving our internal control environment, and we expect to continue to achieve operating efficiencies as we invest in growth and focus on improving long-term profitability.” Financial Restatement The Form 10-K includes audited consolidated financial statements for the years ended December 31, 2012 and 2013, audited consolidated restated financial statements for the year ended December 31, 2011, unaudited consolidated quarterly results for the periods in 2013, and unaudited consolidated restated quarterly results for the periods in 2012 and 2011. The filing also includes selected unaudited restated financial information for the years ended December 31, 2009 and 2010. Filing of the 2013 Form 10-K is a major step toward the Company becoming current in its filings with the SEC, and the Company will now shift financial reporting-related resources to complete its 2014 quarterly and annual filings. As a result of the restatement, and in accordance with GAAP, the Company's financial reporting is changing as described below: Base fees: The Company is presenting revenue recognized from base fee customer billings as a component of net services revenue called net operating fees. Net operating fees consist of (i) gross base fees invoiced to customers; less (ii) any cost savings shared with customers; less (iii) corresponding costs of customers' revenue cycle operations which the Company undertakes to pay pursuant to its RCM agreements. Additionally, net operating fees include fixed fees received from customers. Timing of revenue recognition: The vast majority of revenue generated under the Company's revenue cycle management (RCM) agreements is recognized in periods substantially later than when the Company provides its services, invoices and collects cash from its customers. The Company recognizes revenue under its RCM contracts upon reaching a final determination of the value generated for a customer, which often occurs at the end of a contract. Cash collections for incentive fees and invoiced net operating fees that do not yet meet revenue recognition criteria are added to deferred customer billings within the customer liabilities account on the Company's balance sheet. Software capitalization: Costs associated with internally developed software are expensed, rather than capitalized. However, hardware and purchased software costs that advance the Company's technology capabilities are capitalized in accordance with GAAP. For purposes of better understanding Accretive Health's operating and financial performance from period-to-period, the Company believes it is important to take into account the cash generated from provision of services to customers. As a result, the Company is providing the following non-GAAP measures to provide a more complete understanding of its business: Gross cash generated from customer contracting activities is defined as GAAP net services revenue, plus the change in deferred customer billings. Deferred customer billings include the portion of both (i) invoiced net operating fees and (ii) cash collections related to incentive fees, in each case, that have not met the Company's revenue recognition criteria. Net cash generated from customer contracting activities is defined as net income before net interest income, provision for income taxes, depreciation and amortization expense, share-based compensation, and certain non-recurring costs, plus the change in deferred customer billings. Financial Highlights On a GAAP basis, net services revenue was $504.8 million in 2013 as compared to $72.3 million in 2012. On a non-GAAP basis, gross cash generated from customer contracting activities was $251.6 million in 2013 as compared to $272.4 million in 2012. On a GAAP basis, net income was $130.1 million in 2013 as compared to a net loss of $119.7 million in 2012. On a non-GAAP basis, adjusted EBITDA was $268.7 million in 2013 as compared to a loss of $152.5 million in 2012 and net cash generated from customer contracting activities was $15.6 million in 2013 as compared to $47.6 million in 2012. The Company incurred restatement and other one-time costs of $34.0 million in 2013 and $3.7 million in 2012 related to litigation and other one-time items. The Company currently serves 83 hospitals with collective net patient revenue (NPR) of $17 billion. NPR represents net revenue collected annually by our customers from their patients and is not a measure of the revenue we recognize. Outlook Accretive Health expects to generate gross cash from customer contracting activities of $223 million to $233 million for 2014, and expects net cash generated from contracting activities to be in a range of $5 million to $10 million, excluding restatement and restructuring costs, as well as other one-time costs. Additionally the Company expects gross cash generated from customer contracting activities in 2015 to be in a range of $225 million to $235 million. Net cash generated from customer contracting activities is expected to be in a range of $30 million to $40 million excluding one-time post-restatement related costs. The timing of cash collected from customers for incentive fees creates variability in the Company's non-GAAP measures due to the accounting of incentive fees on a cash basis.